Advertisement
NTLA vs RNA
Which Stock Would AI Choose? Intellia Therapeutics (NTLA) vs. Atrium Therapeutics (RNA) Stock Comparison
Key Takeaways
- NTLA (Intellia Therapeutics) is a late-stage CRISPR gene-editing company approaching its first potential commercial launch, while RNA (Atrium Therapeutics) is a newly independent, preclinical RNA-therapeutics company focused on precision cardiology.
- Intellia recently reported positive Phase 3 data for its lead candidate lonvo-z in hereditary angioedema (HAE) and initiated a rolling Biologics License Application (BLA) submission.
- Atrium launched in February 2026 with roughly $270 million in cash after being spun off from Avidity Biosciences following its acquisition by Novartis; its lead candidates remain preclinical.
- Relative performance and market positioning diverge sharply, reflecting two very different stages of the biotechnology lifecycle.
- Intellia carries more near-term catalysts but also greater commercialization risk, while Atrium offers earlier-stage, higher-risk exposure at a smaller market capitalization.
Introduction
Biotechnology investors frequently weigh late-stage, catalyst-rich developers against earlier-stage platform companies, and the contrast between Intellia Therapeutics and Atrium Therapeutics captures that decision well. NTLA is advancing CRISPR-based gene-editing therapies toward potential approval, while RNA is a young precision-medicine company building an RNA-delivery pipeline in the heart-disease space. This stock comparison is most relevant to traders and investors evaluating relative performance, market positioning, and the trade-off between near-term regulatory milestones and long-horizon clinical risk. Both names sit within the high-volatility biotech sector, making their divergent development stages a useful lens for assessing risk and opportunity.
NTLA Overview and Recent Performance
Intellia Therapeutics (NTLA) is a clinical-stage genome-editing company developing potentially one-time, curative therapies using CRISPR (clustered regularly interspaced short palindromic repeats) technology. Its lead program, lonvo-z, is being developed for hereditary angioedema (HAE), a rare disorder characterized by recurrent, potentially life-threatening swelling. In recent months, the global Phase 3 HAELO study met its primary endpoint, showing that a single infusion of lonvo-z reduced HAE attacks by roughly 87% compared with placebo. Intellia subsequently initiated a rolling BLA submission, with a potential U.S. launch targeted for the first half of 2027.
Sentiment has also been shaped by progress on nex-z, a second lead candidate being co-developed with Regeneron for transthyretin (ATTR) amyloidosis. The U.S. Food and Drug Administration (FDA) lifted clinical holds on the Phase 3 MAGNITUDE and MAGNITUDE-2 studies earlier in 2026, allowing enrollment to resume. Financially, Intellia reported a narrower-than-expected quarterly loss in recent periods and held approximately $628 million in cash and marketable securities as of mid-2026, supported by a roughly $180 million follow-on equity offering. The shares have rallied meaningfully over recent quarters on regulatory progress, though ongoing losses and execution risk remain central to the debate around valuation.
RNA Overview and Recent Performance
RNA is the ticker now used by Atrium Therapeutics, Inc., a precision-cardiology company formed through a spin-off from Avidity Biosciences following Novartis's acquisition of Avidity in early 2026. The ticker's history is notable: RNA previously belonged to Avidity before being reassigned to Atrium upon its independent listing. Atrium is developing RNA (ribonucleic acid) therapeutics delivered directly to heart tissue using a targeted platform combining monoclonal antibodies with small interfering RNA (siRNA).
Atrium launched with roughly $270 million in cash and two lead preclinical candidates, ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both rare, progressive genetic heart conditions with no approved disease-modifying therapies. The company has signaled plans to file an Investigational New Drug (IND) application for ATR 1072 in the second half of 2026. Because Atrium is still in the preclinical and early-filing stage, its share price and market capitalization are comparatively modest, and recent trading activity has been shaped primarily by the spin-off mechanics, capital position, and pipeline timeline rather than clinical data.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated hub where traders can browse the platform's best-performing artificial-intelligence trading bots. Tickeron offers hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the bots best suited to current market conditions earn a place in this rotating selection. Each bot operates with its own trading style, strategy, timeframe, performance history, and set of covered tickers, so no two bots are alike. For investors monitoring names such as NTLA and RNA, reviewing these algorithmically generated signals can provide a useful, data-driven perspective on relative momentum and positioning. Explore the Trending AI Robots section to see which strategies are currently leading the pack.
Head-to-Head Comparison
The two companies differ most fundamentally in development stage. Intellia is a late-stage clinical company with multiple Phase 3 programs and a candidate under active regulatory review, whereas Atrium is an early-stage platform company whose lead assets have not yet entered human trials. This gap drives contrasting risk profiles: Intellia's nearer-term catalysts, such as FDA acceptance and review of its BLA, create potential for significant price movement but also expose investors to regulatory and commercialization execution risk. Atrium, by contrast, faces the classic preclinical risk that its candidates may fail before reaching the clinic, though its spin-off structure and roughly $270 million cash position provide a defined runway.
Sector exposure also differs. Intellia operates in genome editing with applications spanning rare blood and liver-related disorders, while Atrium is concentrated in genetically driven cardiomyopathies, a narrower therapeutic focus. From a market-positioning standpoint, Intellia's larger float and higher trading activity tend to support greater liquidity, while Atrium's smaller capitalization can amplify volatility. Neither company currently generates meaningful product revenue, so both remain dependent on capital markets and clinical execution.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst density, and relative positioning, Tickeron's AI would likely lean toward NTLA over RNA in the current environment. Intellia benefits from a more advanced pipeline, recently positive Phase 3 data, an active regulatory submission, and comparatively deeper liquidity, all of which support a more established, catalyst-rich profile. Atrium's earlier stage and limited public trading history introduce greater uncertainty, even as its cash position and focused pipeline offer a distinct long-horizon narrative. This assessment is probabilistic rather than definitive and reflects relative positioning rather than a forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and RNA is a StrongBuy.
NTLA's Stochastic Oscillator slumps into oversold zone
The Stochastic Oscillator for NTLA moved into oversold territory on October 22, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 201 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 98 of 128 cases where NTLA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTLA as a result. In 85 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
NTLA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 21 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.149) is normal, around the industry mean (2.973). P/E Ratio (-3.341) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RNA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for RNA turned positive on October 07, 2026. Looking at past instances where RNA's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RNA's RSI Indicator exited the oversold zone, 28 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 49 cases where RNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +2.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in 197 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNA as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for RNA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.651) is normal, around the industry mean (2.973). P/E Ratio (-1.500) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.537) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. RNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NTLA | RNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 62 | 85 | |
P/E GROWTH RATING 1..100 | 43 | 16 | |
SEASONALITY SCORE 1..100 | 85 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTLA's Valuation (35) in the Biotechnology industry is in the same range as RNA (37) in the null industry. This means that NTLA’s stock grew similarly to RNA’s over the last 12 months.
NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RNA (100) in the null industry. This means that NTLA’s stock grew similarly to RNA’s over the last 12 months.
RNA's SMR Rating (97) in the null industry is in the same range as NTLA (98) in the Biotechnology industry. This means that RNA’s stock grew similarly to NTLA’s over the last 12 months.
NTLA's Price Growth Rating (62) in the Biotechnology industry is in the same range as RNA (85) in the null industry. This means that NTLA’s stock grew similarly to RNA’s over the last 12 months.
RNA's P/E Growth Rating (16) in the null industry is in the same range as NTLA (43) in the Biotechnology industry. This means that RNA’s stock grew similarly to NTLA’s over the last 12 months.
| NTLA | RNA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Advances ODDS (%) | 3 days ago 78% | 1 day ago 78% |
| Declines ODDS (%) | 1 day ago 88% | 4 days ago 83% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NTLA’s FA Score shows that 0 FA rating(s) are green while RNA’s FA Score has 1 green FA rating(s).
- NTLA’s FA Score: 0 green, 5 red.
- RNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NTLA’s TA Score shows that 3 TA indicator(s) are bullish while RNA’s TA Score has 5 bullish TA indicator(s).
- NTLA’s TA Score: 3 bullish, 5 bearish.
- RNA’s TA Score: 5 bullish, 2 bearish.
Price Growth
NTLA (@Biotechnology) experienced а -1.59% price change this week, while RNA (@Biotechnology) price change was +4.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
NTLA is expected to report earnings on Nov 05, 2026.
RNA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.
| Ticker / NAME | Correlation To RNA | 1D Price Change % | ||
|---|---|---|---|---|
| RNA | 100% | +2.00% | ||
| DYN - RNA | 64% Loosely correlated | -1.87% | ||
| PBYI - RNA | 49% Loosely correlated | +3.30% | ||
| DSGN - RNA | 48% Loosely correlated | -2.24% | ||
| IDYA - RNA | 48% Loosely correlated | +1.83% | ||
| NTLA - RNA | 42% Loosely correlated | -4.21% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VCV | 9.02 | 0.14 | +1.58% |
| INVESCO CALIFORNIA VALUE MUNI Income TRUST | |||
| BRHY | 49.26 | 0.10 | +0.19% |
| iShares High Yield Active ETF (BRHY) | |||
| XOCT | 40.49 | -0.20 | -0.49% |
| FT Vest U.S. Equity Enhance & Moderate Buffer ETF - October (XOCT) | |||
| VCLN | 25.74 | -0.31 | -1.18% |
| Virtus Duff & Phelps Clean Energy ETF (VCLN) | |||
| PSI | 117.28 | -11.84 | -9.17% |
| Invesco Semiconductors ETF (PSI) | |||